Cerebral Atherosclerosis Research With Positron Emission Tomography
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Jun 19, 2025
Trial Information
Current as of July 25, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • acute ischemic stroke patients who admitted within seven days after symptom onset
- Exclusion Criteria:
- • Patients with unstable vital signs or neurological symptoms
- • Patients with estimated glomerular filtration rate less than 30ml/min
- • Patients with uncontrolled diabetes requiring persistent insulin injection
- • During pregnancy or while breastfeeding
- • Patients with impaired consent capacity
- • Patients with diagnosed/treatment for dementia
- • Patients undergoing treatment for malignant tumors or serious autoimmune diseases
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, Jong Ro Gu, Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported